Cover Image

Not for Sale



View/Hide Left Panel

 

Annualized Present Value of Expected Health Benefits (committee median perspective)

 

Annualized Present Values of Expected Net Costs ($million)

 

Predicted Probability of Successful Development (central analysis)

100% Probability of Successful Development

 

Predicted Probability of Successful Development (central analysis)

100% Probability of Successful Development

Vaccine

Rank

Value

Rank

Value

Vaccine

Rank

Value

Rank

Value

Bordetella pertussis

15

40

15

44

Hepatitis A virus (ALV)

15

4

15

4

Rotavirus (ALV human)

16

38

17

42

 

 

 

 

 

 

 

 

 

Hepatitis A virus (subunit)

16

7

16

7

Herpes simplex 1 & 2 (ALV)

17

22

14

45

 

 

 

 

 

 

 

 

 

 

Cytomegalovirus (glycoprotein: children)

17

16

18

29

Neisseria gonorrhoeae

18

8

18

15

 

 

 

 

 

Cytomegalovirus (ALV: nonpregnant adolescent females)

19

5

19

10

Herpesvirus varicellae (normal, children)

18

26

17

28

 

 

 

 

 

Influenza viruses A & B (subunit)

19

31

19

34

Hepatitis A virus (ALV)

20

4

20

5

Hemophilus influenzae type b

20

49

20

54

Hepatitis A virus (subunit)

21

1

21

1

Bordetella pertussis

21

58

21

65

Coccidioides immitis

22

<1

22

<1

Herpes simplex viruses 1 & 2 (glycoprotein)

22

66

22

74



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement